Please assess the completion status of the following clinical trial:

Trial Title: ABI-007 (Nab-Paclitaxel) and Gemcitabine in Treating Women With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed invasive breast cancer~  - Clinical evidence of metastatic disease~  + No bone metastases or other non-measurable disease as the only evidence of metastasis~* Measurable disease, defined as at least 1 measurable lesion~  - The following are considered non-measurable disease:~ * Small lesions (\< 2 cm)~ * Bone lesions~ * Leptomeningeal disease~ * Ascites~ * Pleural or pericardial effusions~ * Inflammatory breast disease~ * Lymphangitis cutis or pulmonis~ * Abdominal masses that are not confirmed and followed by imaging techniques~ * Cystic lesions~* HER2(human epidermal growth factor receptor 2)-positive disease allowed provided patient has received prior treatment with trastuzumab~* No evidence of active brain metastasis, including leptomeningeal involvement~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age~* 18 and over Sex~* Female Menopausal status~* Not specified Performance status~* ECOG 0-1 Life expectancy~* At least 12 weeks Hematopoietic~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 9 g/dL Hepatic~* AST and ALT ≤ 2.5 times upper limit of normal (ULN)~* Bilirubin ≤ 1.5 times ULN Renal~* Creatinine ≤ 1.5 mg/dL Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 30 days after completion of study treatment~* No pre-existing peripheral neuropathy \> grade 1~* No other clinically significant illness or significant medical condition that would preclude study participation~* No history of allergy or hypersensitivity to paclitaxel protein-bound particles in an injectable suspension, paclitaxel, gemcitabine, albumin, drug product excipients, or agents that are chemically similar to study drugs~* No serious medical risk factors involving any of the major organ systems that would preclude study participation~* No active stage III or IV invasive non-breast malignancy within the past 5 years~PRIOR CONCURRENT THERAPY:~Biologic therapy~* See Disease Characteristics Chemotherapy~* No more than 1 prior adjuvant chemotherapy regimen~* No prior chemotherapy for metastatic disease~* At least 6 months since prior adjuvant or neoadjuvant taxane~* More than 2 weeks since prior cytotoxic chemotherapy~* Prior neoadjuvant chemotherapy allowed~* No other concurrent chemotherapy Endocrine therapy~* Prior hormonal treatment as adjuvant therapy or for metastatic disease allowed Radiotherapy~* Prior radiotherapy to target lesion allowed provided there is evidence of disease progression after completion of treatment~* More than 2 weeks since prior radiotherapy, except radiotherapy to a non-target lesion only or single-dose palliative radiotherapy~* No concurrent radiotherapy Surgery~* Not specified Other~* More than 2 weeks since prior investigational drugs~* No concurrent participation in another clinical trial that is studying investigational procedures or therapies~* Concurrent bisphosphonates (e.g., pamidronate or zoledronate) allowed for palliation of pain or lytic lesions from breast cancer

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nab-paclitaxel/Gemcitabine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).